Hot Stocks: Pulmatrix, Inc. (NASDAQ:PULM), TrovaGene, Inc.

On 16 February, Pulmatrix, Inc. (NASDAQ:PULM) and Capsugel have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE™-based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners.

Pulmatrix, Inc. (NASDAQ:PULM) belongs to Healthcare sector. Its performance is -5.88%. On last trading day company shares ended up at $2.32. Pulmatrix, Inc. (NASDAQ:PULM) distance from 50-day simple moving average (SMA50) is -4.65%.

TrovaGene, Inc. (NASDAQ:TROV) announced that it has entered into an Agreement with Fortified Provider Network (Fortified), a direct-contracted preferred provider network administering benefits nationally for over 4 million covered lives. Based on the agreement, Trovagene’s Precision Cancer Monitoring® (PCM) services are covered as an in-network participating laboratory provider for members of Fortified’s network, which includes self-funded employer groups, insurance carriers and regional and local provider networks that process end-user patient claims.

TrovaGene, Inc. (NASDAQ:TROV) shares advanced 6.11% in last trading session and ended the day at $4.86. TROV Gross Margin is -33.30% and its return on assets is -50.80%. TrovaGene, Inc. (NASDAQ:TROV) quarterly performance is -17.21%.

eGain Corp (NASDAQ:EGAN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Analyst Ratings Network.com reports. The firm currently has a $4.25 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 13.64% from the company’s previous close.

On 23 February, eGain Corporation (NASDAQ:EGAN) shares advanced 1.63% and was closed at $3.74. eGain Corporation (NASDAQ:EGAN) year to date (YTD) performance is -12.21%.

Full House Resorts Inc. (NASDAQ:FLL) announced that the Colorado Limited Gaming Control Commission has granted the Company licenses for its pending acquisition of Bronco Billy’s Casino and Hotel in Cripple Creek, Colorado. The Company expects to close on its acquisition of Bronco Billy’s before the end of the first quarter of 2016 once it has received all regulatory approvals, besides those from Colorado, and in conjunction with the refinancing of its primary debt.

Full House Resorts Inc. (NASDAQ:FLL) ended the last trading day at $1.41. Company weekly volatility is calculated as 3.08% and price to cash ratio as 1.92.

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) provides an overview of the Pluristem Therapeutics Inc. ’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pluristem Therapeutics Inc., complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) shares fell -4.48% in last trading session and ended the day at $1.28. PSTI Gross Margin is 96.70% and its return on assets is -37.50%. Pluristem Therapeutics, Inc. (NASDAQ:PSTI) quarterly performance is -14.67%.

Leave a Reply

Your email address will not be published. Required fields are marked *